WESTBURY, N.Y., June 12, 2013 /PRNewswire/ -- Vasomedical,
Inc. (OTC BB: VASO) announced today that Stony Brook Medicine's new
Center for Cardiovascular Wellness and Preventive Research will
feature the Company's EECP Therapy devices in the treatment of
vascular endothelial dysfunction and in preventing the onset and
progression of cerebral, coronary and peripheral vascular
diseases.
According to Stony Brook Medicine's public announcement, the
center was made possible as a result of several recent
philanthropic gifts that were matched dollar for dollar by the
Simons Foundation Challenge Grant, doubling their impact and
totaling in excess of $7.5 million.
The center will conduct groundbreaking research into cardiovascular
health and to identify and develop new options for the treatment
and prevention of coronary artery disease, heart failure and
Alzheimer's disease. It will focus on EECP Therapy, an
FDA-cleared, non-invasive therapeutic device manufactured by
Vasomedical that reduces the workload of the heart and increases
blood flow to the coronary arteries and other organs of the
body.
Dr. Michael Poon, a professor of
Emergency Medicine, Medicine (Cardiology), and Radiology, and
Director of Advanced Cardiovascular Imaging at Stony Brook
Medicine, is leading the research efforts at the new center.
Research at the center could ultimately benefit not only patients
with or at risk of developing coronary artery disease, but also
heart failure and Alzheimer's disease, which are disorders that
could be caused by vascular endothelial dysfunction, as the results
are translated into new approaches to patient care and disease
prevention. Additional exploratory research will examine the
use of EECP Therapy in preventing muscle soreness and injury in
elite athletes.
"At Vasomedical, we have been proponents of EECP Therapy for
almost 20 years, seeing incredible benefits to many different
patient populations. Stony
Brook University was among the first in the United States to adopt EECP Therapy as a
noninvasive treatment for cardiac ailments and has participated in
many published studies. We are grateful for Stony Brook University and Dr. Poon's
continued support and commitment to the research with our
innovative devices," said Dr. John
Hui, Chief Technology Officer of Vasomedical, Inc. "We look
forward to seeing the results of their studies, and are pleased
that such a reputable institution is working to raise public
awareness and support a technology with the potential to
revolutionize the cardiovascular health industry."
Since 1992, there have been more than 190 papers published in
peer-reviewed journals demonstrating the safety, efficacy,
mechanisms of actions as well as economic outcome of EECP Therapy.
Published clinical studies have also shown that EECP Therapy
reduces arterial stiffness, improves cardiovascular and cerebral
health and has a significant effect on improving patients' quality
of life. The Therapy is covered by Medicare and most private
insurance companies for the treatment of refractory angina.
About Vasomedical
Vasomedical, Inc. is a diversified
medical technology company specializing in the manufacture and sale
of medical devices and in the domestic sale of diagnostic imaging
products. The Company's main proprietary products are
EECP® Therapy systems, the gold standard of ECP
treatment. The Company operates through three wholly owned
subsidiaries: VasoSolutions, Vasomedical Global and VasoHealthcare.
VasoSolutions manages and coordinates the design, manufacture and
sales of EECP® Therapy systems, and other medical equipment
operations; Vasomedical Global operates the Company's China-based subsidiaries; and VasoHealthcare
is the operating subsidiary for the exclusive sales representation
of GE Healthcare diagnostic imaging products in certain market
segments. Additional information is available on the Company's
website at www.vasomedical.com.
Except for historical information contained in this release,
the matters discussed are forward-looking statements that involve
risks and uncertainties. When used in this release, words such as
"anticipates", "believes", "could", "estimates", "expects", "may",
"plans", "potential" and "intends" and similar expressions, as they
relate to the Company or its management, identify forward-looking
statements. Such forward-looking statements are based on the
beliefs of the Company's management, as well as assumptions made by
and information currently available to the Company's management.
Among the factors that could cause actual results to differ
materially are the following: the effect of business and economic
conditions; the effect of the dramatic changes taking place in the
healthcare environment; the impact of competitive procedures and
products and their pricing; medical insurance reimbursement
policies; unexpected manufacturing or supplier problems; unforeseen
difficulties and delays in the conduct of clinical trials and other
product development programs; the actions of regulatory authorities
and third-party payers in the United
States and overseas; uncertainties about the acceptance of a
novel therapeutic modality by the medical community; continuation
of the GEHC agreement; and the risk factors reported from time to
time in the Company's SEC reports. The Company undertakes no
obligation to update forward-looking statements as a result of
future events or developments.
Investor Contacts:
Todd
Fromer / Garth Russell
KCSA Strategic Communications
212-896-1215 / 212-896-1250
tfromer@kcsa.com / grussell@kcsa.com
SOURCE Vasomedical, Inc.